Survival of patients with neuroblastoma treated with 125-I MIBG

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 19, Issue 2, 1996, Pages 144-148

  Sisson, James C ^a,b   Shapiro, Brahm ^a   Hutchinson, Raymond J ^a,b   Shulkin, Barry L ^a   Zempel, Shirley ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

125 I metaiodobenzylguanidine; 125 I MIBG; Neuroblastoma

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 125; (3 IODOBENZYL)GUANIDINE I 131;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; HUMAN; NEUROBLASTOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RADIATION DOSE; TREATMENT OUTCOME;

3-IODOBENZYLGUANIDINE; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; IODOBENZENES; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEUROBLASTOMA; PLATELET COUNT; REMISSION INDUCTION; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0029923099     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199604000-00011     Document Type: Article

References (33)

1. Green AA, Hayes FA, Hustu HO. Sequential cyclophosphamide and doxorubicin for induction of complete remission in children with disseminated neuroblastoma. Cancer 1981;48:2310-17.
2. Hutchinson RJ, Sisson JC, Shapiro B, et al. 131-I-Metaiodobenzylguanidine treatment in patients with refractory advanced neuroblastoma. Am J Clin Oncol 1992;15:226-32.
3. 131I]metaiodobenzylguanidine in the treatment of neuroblastoma after conventional therapy. J Nucl Biol Med 1991;35:232-6.
4. 131I]metaiodobenzylguanidine in neuroblastoma: a phase II study in 26 patients. J Nucl Biol Med 1991;35:220-3.
5. 131I]metaiodobenzylguanidine therapy for patients with refractory neuroblastoma. J Nucl Biol Med 1991;35:244-7.
6. 131I]Metaiodobenzylguanidine therapy after conventional therapy for neuroblastoma. J Nucl Biol Med 1991;35:202-6.
7. 131I]-metaiodobenzylguanidine therapy of neuroblastoma: seven years after. J Nucl Biol Med 1991;35:207-15.
8. 131I]-metaiodobenzylguanidine: long-term results in 25 patients. J Nucl Biol Med 1991;35:216-19.
9. 131I]Metaiodobenzylguanidine therapy in advanced neuroblastoma. J Nucl Biol Med 1991;35:224-7.
10. 131I]metaiodobenzylguanidine therapy in advanced neuroblastoma. J Nucl Biol Med 1991;35:241-3.
11. Loevinger R, Japha EM, Brownell GL. Discrete radioisotope sources. In: Hine GJ, Brownell GL, eds. Radiation dosimetry. New York: Academic Press, 1956:743-44.
12. Sisson JC, Hutchinson RJ, Shapiro B, et al. Markers and goals for I-131 MIBG treatment of neuroblastoma. In: DeNardo GL, Lewis JP, Raventos A, Burt RW, eds. Biology of radionuclide therapy. Washington: American College of Nuclear Physicians, 1989:85-93.
13. Dillman LT, Vonder Lage FC. Radionuclide decay schemes and nuclear parameters for use in radiation-dose estimation. In: MIRD pamphlet no. 10. New York: The Society of Nuclear Medicine, 1975:71.
14. Sisson JC, Kwok CS, Hutchinson RJ, et al. Radiation effects of I-131-MIBG and 125-I MIBG. In: DeNardo GL, Lewis JP, Raventos A, Burt RW, eds. Biology of radionuclide therapy. Washington: American College of Nuclear Physicians, 1989:243-51.
15. Sisson JC, Shapiro B, Hutchinson RJ, et al. Predictors of toxicity in treating patients with neuroblastoma by radiolabeled metaiodobenzylguanidine. Eur J Nucl Med 1994;21:46-52.
16. Sisson JC, Hutchinson RJ, Shapiro B, et al. Iodine-125-MIBG to treat neuroblastoma: preliminary report. J Nucl Med 1990;31: 1479-85.
17. 125I]metaiodobenzylguanidine. J Nucl Biol Med 1991;35:255-9.
18. Shimada H, Chatten J, Newton WA Jr, et al. Histopathologic prognostic factors in neuroblastoma tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 1984;73:405-16.
19. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313:1111-16.
20. Hahn HW, Evans AE, Siegel SE, et al. Prognostic importance of serum ferritin in patients with stages IH and IV neuroblastoma: the Childrens Cancer Study Group experience. Cancer Res 1985;45:2843-8.
21. Mangner TJ, Wu JL, Wieland DM. Solid-phase exchange radioiodination of aryl iodides. Facilitation by ammonium sulfate. J Org Chem 1982;47:1484-8.
22. Sisson JC, Shapiro B, Beierwaltes WH, et al. Radiopharmaceutical treatment of malignant pheochromocytoma. J Nucl Med 1984;24:197-206.
23. Loevinger R, Berman M. A revised schema for calculating the absorbed dose from biologically distributed radionuclides. In: MIRD pamphlet no. 1, revised. Society of Nuclear Medicine, 1976.
24. ICRU (1979). Methods of assessment of absorbed dose in clinical use of radionuclides. In: ICRU report 32. Washington: International Commission on Radiation Units and Measurements, 1979.
25. Brownell WH, Ellett WH, Reddy AR. Absorbed fractions for photon dosimetry. In: MIRD pamphlet no. 3. New York: Society of Nuclear Medicine, 1968.
26. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Am Stat Assoc J 1958;53:457-81.
27. Iavarone A, Lasorella A, Servidei T, Riccardi R, Mastrangelo R. Uptake and storage of miodobenzylguanidine are frequent neuronal functions of human neuroblastoma cell lines. Cancer Res 1993;53:304-9.
28. 125I-labeled DNA intercalator in mammalian cells. Radiat Res 1989;118:283-94.
29. 125I. Int J Radiat Biol 1988;53:353-65.
30. Sisson JC. Radionuclide therapy for malignancy: influences of physical characteristics and experience with radiolabeled metaiodobenzylguanidine. In: Ackery D, Batty V, eds. Clinics in oncology. Philadelphia: WB Sanders, 1986:1-21.
31. Ladenstein R, Favrot M, Lasset C, et al. Indication and limits of megatherapy and bone marrow transplantation in high-risk neuroblastoma: a single centre analysis of prognostic factors. Eur J Cancer 1993;29:947-56.
32. Fox F, Davidson J, Thomas LB. Maturation of sympathicoblastoma into ganglioneuroma. Report of 2 patients with 20- and 46-year survivals respectively. Cancer 1959;12:108-16.
33. Griffin ME, Bolande RP. Familial neuroblastoma with regression and maturation to ganglioneurofibroma. Pediatrics 1969;43:377-82.